The Association of Cancer Physicians responds to "Cancer drugs, survival, and ethics"
BMJ
.
2016 Dec 5:355:i6487.
doi: 10.1136/bmj.i6487.
Authors
Adam Dangoor
1
,
Johnathan Joffe
2
,
Adam Januszewski
3
,
Janine Mansi
4
,
David Cunningham
5
,
Peter Selby
6
;
17 other authors and members of the Association of Cancer Physicians, UK
Affiliations
1
Bristol Cancer Institute, Bristol Haematology and Oncology Centre, Bristol BS2 8ED, UK.
2
Huddersfield Royal Infirmary, Huddersfield, UK.
3
Imperial College, London, UK.
4
Guy's and St Thomas' Hospital, London, UK.
5
Royal Marsden Hospital, London, UK.
6
St James's University Hospital, Leeds, UK.
PMID:
27920029
DOI:
10.1136/bmj.i6487
No abstract available
Publication types
Letter
MeSH terms
Antineoplastic Agents
Codes of Ethics
Ethics
Ethics, Medical*
Humans
Neoplasms
Physicians*
Substances
Antineoplastic Agents
Grants and funding
RP-PG-0707-10101/DH_/Department of Health/United Kingdom